From: Alternative mRNA splicing in anthracycline-induced cardiomyopathy – a COG-ALTE03N1 report
Variables | Cases (N = 32) | Controls (N = 32) | p-valuea |
---|---|---|---|
Age at primary cancer diagnosis in years | |||
Median (IQR) | 9.5 (3.8–14.7) | 10.7 (3.9–15.1) | 0.71 |
Sex, N (%) | |||
Female | 19 (59.4) | 16 (50.0) | 0.45 |
Male | 13 (40.6) | 16 (50.0) | |
Cumulative anthracycline exposure, N (%) | |||
< 250 mg/m2 | 13 (40.6) | 20 (62.5) | 0.08 |
≥ 250 mg/m2 | 19 (59.4) | 12 (37.5) | |
Chest Radiation | |||
Yes (N, %) | 13 (40.6) | 6 (18.8) | 0.05 |
Dose in cGy (Mean ± SD) | 1335.6 ± 1953.7 | 524.1 ± 1185.5 | 0.044 |
Race/Ethnicity (N, %) | |||
Non-Hispanic white | 15 (46.9) | 15 (46.9) | Matched |
Hispanic | 9 (28.1) | 9 (28.1) | |
Black/African American | 5 (15.6) | 5 (15.6) | |
Asian | 3 (9.4) | 2 (6.3) | |
Mixed race/ethnicity | 0 (0.0) | 1 (3.1) | |
Primary Diagnosis, N (%) | |||
Acute lymphoblastic leukemia | 7 (21.9) | 7 (21.9) | Matched |
Acute myeloid leukemia | 2 (6.3) | 2 (6.3) | |
Ewing sarcoma | 4 (12.5) | 4 (12.5) | |
Hodgkin lymphoma | 4 (12.5) | 4 (12.5) | |
Neuroblastoma | 4 (12.5) | 4 (12.5) | |
Non-Hodgkin lymphoma | 5 (15.6) | 5 (15.6) | |
Osteosarcoma | 4 (12.5) | 4 (12.5) | |
Soft tissue sarcoma | 2 (6.3) | 2 (6.3) | |
CVRF, N (%) | |||
No | 18 (56.3) | 31 (96.9) | 0.0006 |
Yes | 12 (37.5) | 1 (3.1) | |
Missing | 2 (6.3) | 0 (0.0) | |
Time from diagnosis to cardiac event for cases or time to enrollment for controls in years | |||
Median (IQR) | 2.4 (0.6–7.7) | 9.4 (6.4–13.7) | 0.0001 |